These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 12904715)

  • 41. The additive pulmonary vasodilatory effects of inhaled prostacyclin and inhaled milrinone in postcardiac surgical patients with pulmonary hypertension.
    Haraldsson s A; Kieler-Jensen N; Ricksten SE
    Anesth Analg; 2001 Dec; 93(6):1439-45, table of contents. PubMed ID: 11726420
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pulmonary Hypertension Related to Chronic Obstructive Pulmonary Disease and Diffuse Parenchymal Lung Disease: A Focus on Right Ventricular (Dys)Function.
    Tseng S; Stanziola AA; Sultan S; Henry K; Saggar R; Saggar R
    Heart Fail Clin; 2018 Jul; 14(3):403-411. PubMed ID: 29966637
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Endothelin receptor antagonist bosentan improves the dermal sclerosis in a patient with systemic sclerosis.
    Nishibu A; Sakai E; Oyama N; Yamamoto T
    Australas J Dermatol; 2012 May; 53(2):e32-3. PubMed ID: 22571581
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of aerosolized prostacyclin and inhaled nitric oxide on experimental hypoxic pulmonary hypertension.
    Max M; Kuhlen R; Dembinski R; Rossaint R
    Intensive Care Med; 1999 Oct; 25(10):1147-54. PubMed ID: 10551974
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacologic treatment of pulmonary arterial hypertension.
    Ramani GV; Gill S
    Curr Pharm Des; 2013; 19(22):3963-73. PubMed ID: 23228314
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease.
    Ahmadi-Simab K; Hellmich B; Gross WL
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():44-8. PubMed ID: 16919010
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Pulmonary hypertension in COPD and interstitial lung diseases].
    Markart P; Ghofrani HA; Grimminger F; Günther A
    Dtsch Med Wochenschr; 2009 Aug; 134 Suppl 5():S164-6. PubMed ID: 19718606
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series.
    McLaughlin VV; Genthner DE; Panella MM; Hess DM; Rich S
    Ann Intern Med; 1999 May; 130(9):740-3. PubMed ID: 10357693
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Development of nonspecific interstitial pneumonitis associated with long-term treatment of primary pulmonary hypertension with prostacyclin.
    Kesten S; Dainauskas J; McLaughlin V; Rich S
    Chest; 1999 Aug; 116(2):566-9. PubMed ID: 10453891
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Pulmonary hypertension associated with connective tissue diseases].
    Sanchez O; Humbert M; Sitbon O; Nunes H; Garcia G; Simonneau G
    Rev Med Interne; 2002 Jan; 23(1):41-54. PubMed ID: 11859694
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oral sildenafil prevents and reverses the development of pulmonary hypertension in monocrotaline-treated rats.
    Liu H; Liu ZY; Guan Q
    Interact Cardiovasc Thorac Surg; 2007 Oct; 6(5):608-13. PubMed ID: 17670742
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interstitial pneumonia and pulmonary hypertension associated with suspected ehrlichiosis in a dog.
    Toom ML; Dobak TP; Broens EM; Valtolina C
    Acta Vet Scand; 2016 Jul; 58(1):46. PubMed ID: 27388158
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Response to pulmonary vasodilator treatment in a former smoker with combined interstitial lung disease complicated by pulmonary hypertension: case report and review of the literature.
    Mercurio V; Carlomagno G; Fazio S
    Heart Lung; 2012; 41(5):512-7. PubMed ID: 22054725
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of pulmonary hypertension in patients with chronic obstructive pulmonary disease: position of vasodilators with special focus on urapidil.
    Adnot S; Samoyeau R; Weitzenblum E
    Blood Press Suppl; 1995; 3():47-57. PubMed ID: 8535542
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pulmonary hypertension due to interstitial lung disease.
    King CS; Nathan SD
    Curr Opin Pulm Med; 2019 Sep; 25(5):459-467. PubMed ID: 31365380
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Efficacy of combination therapy with bosentan and sildenafil for refractory pulmonary arterial hypertension associated with fibrotic lung in systemic sclerosis].
    Gocho K; Sugino K; Ota H; Kusano E; Takai Y; Homma S
    Nihon Kokyuki Gakkai Zasshi; 2010 Oct; 48(10):786-90. PubMed ID: 21066870
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhaled Therapies for Pulmonary Hypertension.
    Hill NS; Preston IR; Roberts KE
    Respir Care; 2015 Jun; 60(6):794-802; discussion 802-5. PubMed ID: 26070575
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Improving Survival in Patients with Pulmonary Arterial Hypertension: Focus on Intravenous Epoprostenol.
    Demerouti E; Karyofyllis P; Manginas A; Anthi A; Karatasakis G; Athanassopoulos G; Voudris V
    Am J Cardiovasc Drugs; 2019 Apr; 19(2):99-105. PubMed ID: 30671881
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Inhalative strategies for improvement of pulmonary hemodynamics and gas exchange in sepsis and severe pulmonary hypertension].
    Grimminger F; Rose F; Ghofrani HA; Schermuly RT; Weissmann N; Olschewski H; Walmrath D; Seeger W
    Z Kardiol; 2000 Jun; 89(6):477-84. PubMed ID: 10929431
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pulmonary hypertension in diffuse parenchymal lung diseases - is there any benefit of PAH-specific therapy?
    Szturmowicz M; Kacprzak A; Kuś J
    Adv Respir Med; 2017; 85(4):216-223. PubMed ID: 28871590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.